- Home
- NBP vs MYGN Comparison
NBP vs MYGN Comparison
Compare NBP & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | MYGN |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 444.2M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | NBP | MYGN |
|---|---|---|
| Price | $2.55 | $4.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $9.00 | $7.64 |
| AVG Volume (30 Days) | 919.8K | ★ 1.3M |
| Earning Date | 04-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.89 |
| Revenue Next Year | N/A | $5.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $2.10 | $3.76 |
| 52 Week High | $5.19 | $8.59 |
Technical Indicators
Market Signals| Indicator | NBP | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 54.92 |
| Support Level | $2.10 | $4.23 |
| Resistance Level | $3.80 | $5.67 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 65.67 | 87.97 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.